Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 12:19PM ET
27.29
Dollar change
+0.04
Percentage change
0.13
%
IndexRUT P/E13.19 EPS (ttm)2.07 Insider Own1.47% Shs Outstand166.98M Perf Week1.17%
Market Cap4.56B Forward P/E10.78 EPS next Y2.53 Insider Trans-0.63% Shs Float164.62M Perf Month-8.44%
Income355.76M PEG0.53 EPS next Q0.63 Inst Own106.25% Short Float8.56% Perf Quarter-2.76%
Sales1.66B P/S2.74 EPS this Y84.55% Inst Trans-1.28% Short Ratio7.47 Perf Half Y2.77%
Book/sh7.20 P/B3.79 EPS next Y-4.77% ROA19.68% Short Interest14.08M Perf Year7.56%
Cash/sh4.63 P/C5.89 EPS next 5Y24.80% ROE35.93% 52W Range20.46 - 32.88 Perf YTD-1.64%
Dividend Est.- P/FCF12.90 EPS past 5Y- ROI22.72% 52W High-17.01% Beta0.56
Dividend TTM- Quick Ratio2.50 Sales past 5Y10.61% Gross Margin82.17% 52W Low33.36% ATR (14)0.76
Dividend Ex-Date- Current Ratio2.86 EPS Y/Y TTM320.93% Oper. Margin17.44% RSI (14)42.13 Volatility2.39% 2.58%
Employees2100 Debt/Eq0.31 Sales Y/Y TTM49.61% Profit Margin21.39% Recom2.15 Target Price34.83
Option/ShortYes / Yes LT Debt/Eq0.30 EPS Q/Q485.63% Payout0.00% Rel Volume0.23 Prev Close27.25
Sales Surprise4.21% EPS Surprise-50.83% Sales Q/Q23.89% EarningsFeb 15 BMO Avg Volume1.89M Price27.29
SMA20-4.14% SMA50-3.94% SMA2000.72% Trades Volume199,557 Change0.13%
Date Action Analyst Rating Change Price Target Change
Mar-19-24Initiated Robert W. Baird Outperform $37
Feb-20-24Downgrade UBS Neutral → Sell $25
Nov-20-23Resumed JP Morgan Neutral $33
Oct-24-23Upgrade Evercore ISI In-line → Outperform
Oct-17-23Initiated UBS Neutral $31
Nov-03-22Upgrade Piper Sandler Neutral → Overweight $26 → $30
Oct-14-22Upgrade BofA Securities Underperform → Neutral $27 → $25
Aug-16-22Initiated Piper Sandler Neutral $26
Apr-22-22Resumed Goldman Buy $35
Apr-20-22Initiated Goldman Buy $35
Mar-21-24 03:03PM
Mar-18-24 07:01PM
Mar-15-24 06:15PM
Mar-13-24 12:45PM
Mar-12-24 09:50AM
10:00AM Loading…
Mar-10-24 10:00AM
Mar-08-24 09:45AM
Mar-07-24 06:15PM
07:00AM
Feb-29-24 06:15PM
Feb-23-24 09:50AM
Feb-21-24 09:45AM
Feb-16-24 10:18AM
Feb-15-24 02:40PM
01:34PM
09:30AM Loading…
09:30AM
07:37AM
07:30AM
07:00AM
Feb-12-24 09:16AM
Feb-08-24 04:10PM
04:00PM
10:00AM
Feb-07-24 06:15PM
Feb-02-24 02:15AM
Feb-01-24 06:15PM
05:00PM
Jan-30-24 12:10PM
Jan-26-24 06:15PM
Jan-15-24 04:51PM
06:15PM Loading…
Jan-12-24 06:15PM
Jan-03-24 04:00PM
07:00AM
Dec-27-23 11:45AM
Dec-22-23 06:15PM
Dec-20-23 02:15PM
12:15PM
Dec-18-23 01:45PM
Dec-14-23 10:45AM
06:05AM
Dec-13-23 04:08AM
Dec-11-23 02:30PM
Dec-01-23 06:16PM
Nov-29-23 03:15PM
Nov-24-23 11:31AM
Nov-21-23 04:00PM
11:45AM
Nov-20-23 01:45PM
Nov-16-23 10:30AM
Nov-15-23 08:57AM
07:15AM
07:00AM
Nov-14-23 01:45PM
10:33AM
05:50AM
Nov-13-23 09:50PM
12:45PM
Nov-10-23 03:00PM
Nov-09-23 11:12AM
Nov-08-23 11:30AM
Nov-07-23 04:00PM
Nov-04-23 12:16PM
Oct-31-23 05:08PM
01:30PM
Oct-26-23 12:00PM
10:37AM
Oct-25-23 12:38PM
09:30AM
07:23AM
07:00AM
Oct-24-23 09:51AM
Oct-23-23 04:00PM
02:00PM
08:00AM
Oct-19-23 10:01AM
Oct-18-23 06:15PM
04:00PM
Oct-16-23 12:30PM
Oct-13-23 10:45AM
Oct-11-23 12:00PM
Oct-10-23 05:00PM
07:00AM
Sep-21-23 01:00PM
Sep-19-23 11:05AM
Sep-18-23 01:15PM
Sep-15-23 06:15PM
Sep-13-23 10:50AM
Sep-11-23 07:00AM
Sep-08-23 06:15PM
Sep-07-23 03:15PM
11:31AM
09:30AM
07:00AM
Sep-06-23 09:50AM
Sep-05-23 04:00PM
Sep-01-23 06:30PM
11:31AM
Aug-31-23 02:45PM
11:02AM
07:00AM
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nichols Christian ToddSVP, Chief Commercial OfficerMar 18 '24Sale28.1010,417292,74065,911Mar 18 04:02 PM
Parisi Samuel JosephVP, Finance (Interim PAO)Feb 27 '24Sale29.652,55975,8747,717Feb 27 04:09 PM
LAURENCIN CATO TDirectorFeb 15 '24Option Exercise22.522,69060,57917,859Feb 16 04:01 PM
LAURENCIN CATO TDirectorFeb 15 '24Sale31.852,69085,67615,169Feb 16 04:01 PM
LAURENCIN CATO TDirectorJun 08 '23Option Exercise22.972,63860,59510,117Jun 08 04:31 PM
LAURENCIN CATO TDirectorJun 08 '23Sale31.852,63884,0207,479Jun 08 04:31 PM
LAURENCIN CATO TDirectorJun 07 '23Option Exercise22.972,80064,31610,279Jun 07 05:12 PM
LAURENCIN CATO TDirectorJun 07 '23Sale31.502,80088,2007,479Jun 07 05:12 PM
Nichols Christian ToddSVP, Chief Commercial OfficerMay 30 '23Option Exercise20.4319,634401,12368,118May 30 08:16 PM
Nichols Christian ToddSVP, Chief Commercial OfficerMay 30 '23Sale28.9327,134784,86240,984May 30 08:16 PM
Wysenski NancyDirectorMay 09 '23Option Exercise31.1341,2501,284,11257,079May 10 04:34 PM
Wysenski NancyDirectorMay 09 '23Sale31.2441,2501,288,78615,829May 10 04:34 PM